drugset / Trial / NCT00370968

Zinc-ORS in Severe and Complicated Acute Diarrhea

NCT00370968 ↗

RandomizedParallel-groupDouble-blindTreatment

Summary

Three-hundred-and-fifty-two males aged 1-36 months with acute non-dysenteric diarrhoea and no systemic illness will be enrolled in this clinical trial. Eligible children will be stratified by their age (1up to 5 months, 6-35 months). Within the two age strata the patients will be randomized to receive zinc-ORS (fortified with 40 mg elemental zinc as zinc gluconate per litre) or standard WHO ORS. The major outcome measures will be stool output and duration of diarrhea. The safety of administering zinc will be determined by examining the effect of zinc ingestion on vomiting, sodium and potassium homeostasis, plasma zinc and copper, and iron stores and concentration of serum transferrin receptor.

Timeline

Start
2003-09
Primary completion
—
Completion
2006-12

Outcome

Missed primary endpoint

paper ORS containing zinc does not reduce duration or stool volume of acute diarrhea in hospitalized children. PMID 21788757 ↗

paper The time to recovery was also similar in the 2 groups (hazard ratio 1.06 [95% confidence interval 0.88-1.27]). PMID 21788757 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Zinc Sulfate Unknown 0.04 mg/ml Oral

Indications